PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot Overview – Biogen’s prescription pharmaceutical business will see stable performance over the medium term. Key themes –  Biogen’s flagship MS portfolio – Tecfidera, Avonex, Plegridy, and Tysabri – remains incredibly stable  Spinraza revenues will plateau during the forecast period due to competition from newer products  Biogen’s revival of aducanumab is a surprise and will add significant revenue during the forecast period.
Model updates (22 July 2020)
Tecfidera forecast adjusted significantly lower due to litigation outcome resulting in earlier generic competition Vumerity forecast adjusted lower due to later expected launch in EU and RoW Imraldi forecast adjusted lower in EU.
Model updates (22 April 2020)
Vumerity forecast adjusted lower due to continued slow launch.
Model updates (30 January 2020)
Spinraza forecast adjusted higher due to continued international growth Avonex forecast adjusted lower due to continued competition in multiple sclerosis Vumerity forecast adjusted lower due to initial launch trends.
Model updates (28 October 2019)
Spinraza forecast adjusted lower in the US Imraldi forecast adjusted higher due to quicker adoption Ocrevus royalty forecast adjusted higher due to continued ramp of Ocrevus in all types of MS Aducanumab forecast added.
Model updates (23 July 2019)
Tecfidera sales adjusted lower in 2028 due to patent expiration Tysabri sales adjusted higher due to less impact from competition Spinraza sales adjusted lower due to pending competition from Zolgensma and risdiplam Benepali sales adjusted lower due to stabilization in five major EU markets and RoW Rituxan/Gazyva royalties adjusted higher due to lower than expected biosimilar impact Ocrevus royalties adjusted higher due to strong momentum in the US and other global approvals Vumerity launch delayed to 2020 in the US Aducanumab removed from forecast after failing Phase III ENGAGE and EMERGE trials BIIB067 forecast added.
Our reports have been used by over 10K customers, including:
Anti-obesity Prescription Drugs Market Research Report by Drug Class (Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate), by Age Group (Adult and Pediatric), by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Anti-obesity Prescription...
112 pages •
By Euromonitor International
• Nov 2020
Consumer health in Slovakia is expected to show considerable resilience in response to the COVID-19 pandemic. Despite troubling economic circumstances, many consumers saw consumer health products as indispensable and continued to buy them despite decreasing incomes. Initial stockpiling in March did cause some product shortages, particularly...
The North America Over the Counter (OTC) Drugs Market is anticipated to grow with a CAGR of 2.7%, during the forecast period. The OTC drugs market is innovation-driven and relies on the advent of innovative drugs for different disease complexities and vary in their degree of intensity, and efficacy. The product innovations in OTC drugs...
The global osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The growth of this market is driven significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number...
The North America dermatology treatment devices market is expected to reach US$ 3,908.11 million in 2027 from US$ 2,310.03 million in 2019. The market is estimated to grow with a CAGR of 7.0% from 2020 to 2027. The growth of this market is attributed to the key driving factors such as growing incidences of skin disorders and skin cancer...
The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3% during the forecast period. Market growth can be largely attributed to factors such as the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding...